SENATE BILL NO. 198                                                                         
"An Act relating to a study of the effectiveness and cost of providing long-acting                                      
reversible contraception to women with substance abuse disorders."                                                      
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF ALASKA:                                                                
* Section 1. The uncodified law of the State of Alaska is amended by adding a new section                          
to read:                                                                                                                
UNIVERSITY OF ALASKA; STUDY OF LONG-ACTING REVERSIBLE                                                                   
CONTRACEPTION FOR WOMEN WITH SUBSTANCE ABUSE DISORDERS. (a) The                                                         
University of Alaska Anchorage Center for Alcohol and Addiction Studies shall conduct a                                 
study to evaluate the effectiveness of providing long-acting reversible contraception to                                
women with substance abuse disorders who are at high risk for unintended pregnancies that                               
may result in prenatal drug or alcohol exposure. The university shall collaborate with                                  
hospitals and health care providers in the state who treat women with substance abuse                                   
disorders to                                                                                                            
(1)  establish an advisory council to assist with designing and implementing                                 
the study;                                                                                                              
(2)  evaluate best practices for treating women and children when there is a                                 
high risk of neonatal abstinence syndrome or fetal alcohol spectrum disorders;                                          
(3)  facilitate the creation of an effective network of hospitals and service                                
providers for the sharing of best practices;                                                                            
(4)  identify women and children to participate in the study on a voluntary                                  
basis;                                                                                                                  
(5)  provide long-acting reversible contraception to participants in the study                               
who are at high risk for unintended pregnancies that may result in prenatal drug or alcohol                             
exposure;                                                                                                               
(6)  evaluate the costs of providing long-acting reversible contraception and the                                       
effectiveness of long-acting reversible contraception in reducing the occurrence of neonatal                            
abstinence syndrome and fetal alcohol spectrum disorders;                                                               
(7)  develop a cohort of women and children, through the study, who can be                                              
evaluated in later studies that assess the costs and long-term effects of neonatal abstinence                           
syndrome and fetal alcohol spectrum disorders in the state; and                                                         
(8)  provide a data-driven framework to establish a comprehensive strategy for                                          
using long-acting reversible contraception to reduce the occurrence of neonatal abstinence                              
syndrome and fetal alcohol spectrum disorders in the state.                                                             
(b)  The University of Alaska shall complete a final report and two interim reports                                     
describing the results of the study, evaluating the cost and effectiveness of providing long-                           
acting reversible contraceptives to women in substance abuse treatment programs, and                                    
providing recommendations for treating pregnant women who have substance abuse disorders                                
and improving the health and well-being of children who have been exposed to alcohol or                                 
drugs before birth. The university shall complete the first interim report not later than June 30,                      
2019, the second interim report not later than June 30, 2020, and the final report not later than                       
June 30, 2021, and submit each report to the senate secretary and the chief clerk of the house                          
of representatives and notify the legislature that each report is available.                                            
(c)  In this section,                                                                                             
(1)  "fetal alcohol spectrum disorder" means a condition of impaired brain                                              
function in the range of permanent birth defects caused by maternal consumption of alcohol                              
during pregnancy;                                                                                                       
(2)  "long-acting reversible contraception" means a method of birth control that                             
prevents a woman from becoming pregnant for an extended time without requiring action by                                
the user, but that can be reversed to allow the woman to become pregnant;                                               
(3)  "neonatal abstinence syndrome" describes symptoms that occur in a                                       
newborn child who was exposed to addictive drugs before birth as a result of the                                        
discontinuation of exposure to the drugs at birth.                                                                      
* Sec. 2. Section 1 of this Act is repealed June 30, 2021.                                                         